Dr. Jens Hoffmann CEO
From 1984 to 1989 Dr. Hoffmann studied pharmacy at the University of Greifswald and obtained his Diploma in Pharmacy and Experimental Pharmacology and Toxicology. He started working in Oncology Research in 1989 in the Department of Clinical Pharmacology at the Central Institute for Cancer Research in Berlin-Buch. In 1991 he worked as a guest scientist at the German Cancer Research Center in Heidelberg. He finished his PhD thesis “Investigations on the phenomenon of multidrug resistance, markers of resistance, and correlation with clinical outcome” in 1995 and obtaind the PhD degree from the Humboldt University Berlin.
He took a first postdoc position at Schering AG in the Experimental Oncology working on tumor angiogenesis. During a second Postdoctoral Training he worked at the University of Pittsburgh, School of Medicine, Department of Pharmacology on “Redox regulation and cell death”
In 1997 he joined Schering AG as group leader in Oncology Research. His main research field was the preclinical development of new cancer drugs, translational research, and small animal imaging. For that purpose, he developed several new in vivo models, especially for tumor angiogenesis, sarcomas, and hormone dependent cancers. In 2009 he joined EPO as managing director.
Dr. Hoffmann has special expertise for pharmacological investigations concerning endocrine tumors, biomarker research was another focus of his scientific work. He has published more than 30 original articles in peer reviewed journals and as many patents. Dr. Hoffmann is member of the German Cancer Foundation and the American Association for Cancer Research (AACR).
Dr. Iduna Fichtner COO
Dr. habil. nat. Iduna Fichtner studied pharmacy in Jena and Halle and acquired several qualifications in the field of experimental pharmacology. She has been working in oncology since 1977. Until 1991 she was department leader at the Central Institute for Cancer Research of Academy of Sciences. Between 1992 and 2016 she was a senior scientist and the head of the group "Experimental Pharmacology" at the Max-Delbrück-Center for Molecular Medicine. Additionally, she was responsible for Technology Transfer of that institution between 1998 and 2002.
Her main research field is the preclinical evaluation and development of novel potential cancerostatics. For that purpose, several new in vivo models, especially for leukaemias, breast and colon carcinomas were established and characterised for clinic-relevance and equipment with molecular targets.
Iduna Fichtner has special expertise for pharmacological investigations concerning liposomal and other vesicular drugs, and for the study of immuno- and gene-therapeutics. The definition of growth and engraftment conditions for normal and leukaemic stem cells were another focus of her scientific work.
She has published more than 150 original articles in peer reviewed journals.
Mrs. Fichtner is member of the German Cancer Foundation, the European Organisation for Research and Treatment of Cancer (EORTC) and the American Association for Cancer Research (AACR). Within the EORTC she was elected for three years as chairperson of Screening and Pharmacology Group and is presently speaker of the joint initiative for the development of NCI/EORTC/CRUK derived anticancer agents.
Further on, she is member of the Central European Society for Anticancer Drug Research (CESAR)-EWIV and within that organization she was for several years the head of the Working Group of New Drug Development in Oncology (AWO).
She is member of the Editorial Board of the AACR journal Molecular Cancer Tharapeutics.
Prof.Dr. Wolfgang Walther CSO
Prof. Dr. Wolfgang Walther studied biochemistry from 1979 – 1984 and graduated in biochemistry at the
Leipzig University, Germany. He then started to work in the field of cancer research at the Central Institute for Cancer Research at the Academy of Sciences in Berlin-Buch and he received his PhD
in 1989 in Biochemistry at the Academy of Sciences, Berlin, Germany. During this time he completed his postgraduate training in Biochemical Medicine at the Academy of Medical Education.
In 1989 he worked as visiting fellow at the Imperial Cancer Research Fund (ICRF) in London, UK. From 1994 to 1995 he was visiting scientist as Alexander von Humboldt-fellow at the National Cancer Institute (NCI) in Frederick, MD, USA. He was invited as guest consultant for several times between 1996 and 2003 at the NCI, Frederick, MD. From 1996 he was PI for gene therapy at the Max-Delbrück-Center for Molecular Medicine (MDC), and from 2000 to 2006 he worked at the Charité, University Medicine Berlin in the Department of Surgery and Surgical Oncology. Since 2007 he is working at the Experimental and Clinical Research Center (ECRC), Charité Berlin. In 2004 he received his habilitation in biochemistry at the Charité, Berlin and was appointed as professor at the Charité in 2012. Since 2015 Prof. Walther joined the EPO team as CSO.
His main research focus is the preclinical evaluation and development of novel therapeutic modalities to treat solid cancers and metastasis. This includes resistance reversing, metastasis interfering strategies and the development of nonviral gene therapeutics in preclinical and clinical approaches. In this context his work is tightly associated with the development of in vivo models and their uses for translational cancer research to test the applicability of new therapeutic approaches, particularly for treatment of solid cancers.
Prof. Walther published more than 90 original articles in international peer reviewed journals, edited scientific books and filed several patents. He is member of the German Cancer Foundation, of the American Association for Cancer Research (AACR) and he is member of editorial boards of peer reviewed international scientific journals.
2012 EPO has currently customers from more than 125 scientific institutes, biotech and pharmaceutical companies worldwide.
1997 EPO was founded by Dr. I. Fichtner and Dr. Ch. Nowak in 1997 as a spin-off from the Max-Delbrück-Center for Molecular Medicine [MDC] and has been constantly growing.